

Identification of IL13 C1923T as a Single Nucleotide Polymorphism for Asthma in Children from Mauritius

Kamleshun Ramphul, MD, Li Hua, PhD, Yi Xiao Bao, PhD, Jing Yang Li, MD,
Quan Hua Liu, PhD, Ruo Xu Ji, PhD, and Ding Zhu Fang, PhD

Background: Research increasingly suggests that asthma is a familial and hereditary disorder and that genetic and environmental factors play a key role in its pathogenesis.

Objective: The aim of this study was to investigate the associations between 10 single nucleotide polymorphism (SNP) loci in the development of asthma in children from the Mauritian population.

Methods: The study population consisted of 193 children with asthma and 189 healthy controls from the Mauritian population. Asthma was diagnosed in accordance with the American Thoracic Society criteria. TaqMan real-time quantitative polymerase chain reaction was used to detect the genotypes of the SNP loci.

Results: No statistically significant differences ($p > 0.05$) were found between the experimental and control group in genotype distribution among nine of the loci (MS4A2 E237G, MS4A2 C-109T, ADRB2 R16G, IL4RA Q551R, IL4RA I75V, IL4 C-590T, IL13 A2044G, IL13 C-1112T, and CHI3L1 C-131G). However, the frequency of IL13 C1923T TT in the asthma group was significantly higher than in the control group (odds ratio = 2.119, $p = 0.033$) suggesting that carriers of IL13 C1923T TT in the Mauritian population may have a more significant risk of developing asthma.

Conclusion: The nine loci have little contribution to the development of childhood asthma in the Mauritian population. IL13 C1923T TT has been detected to be the susceptible genotype and may have a significant effect on the pathogenesis of childhood asthma in the Mauritian population.

Introduction

ASTHMA IS ONE of the most common chronic inflammatory lung diseases, and it is believed to affect 300 million people worldwide,¹ including 10 million children.² Its incidence and mortality among the pediatric groups is on the rise, and its impact on society is substantial. Recent developments in molecular biology and genetics suggest that asthma is an hereditary disorder based on several factors, including genes.^{3,4}

A significant amount of research has been done over the last decade to find gene loci predisposing to asthma and other atopic diseases. The elevated levels of total immunoglobulin (Ig) E and allergy-specific IgE are hallmarks of allergic inflammation.⁵ Ober *et al.* recently reviewed 118 genes associated with asthma or atopy, and 25 of these have been replicated in at least six studies and thus are believed to be the susceptible genes most likely to be associated with asthma and atopy.⁶ The current study examined the roles of 10 single nucleotide polymorphisms (SNPs; MS4A2 E237G, MS4A2 C-109T, ADRB2 R16G,

IL4RA Q551R, IL4RA I75V, IL4 C-590T, IL13 A2044G, IL13 C1923T, IL13 C-1112T, and CHI3L1 C-131G) with the development of asthma in children from the Mauritian population. The C-109T polymorphism of MS4A2 encoding the β chain of the high-affinity IgE receptor has been associated with increased plasma IgE levels⁷ and the release of proinflammatory factors in asthmatic airways.^{8,9} The IL-13 gene is found on chromosome 5q31–33 and has been significantly associated with allergic asthma.¹⁰ The T allele of the IL13 C1923T and IL13 C1112T have both shown to be significantly associated with increased risk of asthma,^{11,12} and rs1295686 is involved in the dysregulation of total IgE.¹³ ADRB2 R16G, a polymorphism of the β 2-adrenergic receptor (β 2AR) gene, may be strongly associated with hyper-responsiveness of the airway following activation by β 2-adrenoceptor agonists.¹⁴ Associations of IL-4 and the IL-4 receptor alpha chain (IL4RA) gene with asthma have also been reported in some studies,^{15,16} and CHI3L1 has been shown to be a susceptibility gene for asthma and bronchial hyper-responsiveness.¹⁷ Recent meta-analysis conducted by Nie *et al.* has shown

that IL4RA Q551R polymorphism predisposes children but not adults to asthma, and its exact role in the pathogenesis is still not conclusive.¹⁸

Methods

Subjects

This study included 382 unrelated individuals from Mauritius (193 children with asthma and 189 adult healthy controls). Informed consent was obtained from the parents or guardians.

All patients were recruited from the Sir Seewoosagar Ramgoolam National Hospital. The 193 children with asthma were aged between 3 and 12 years old, and there was an even distribution of males and females. All asthma patients were clinically stable and had at least one active asthma symptom. Asthma was defined according to the guidelines of the American Thoracic Society.¹⁹ The patient group consisted of children who had been diagnosed with asthma for at least 1 year. They had also had more than two asthma episodes that included symptoms such as wheezing during the past year, and were still following treatment for their asthma. The criteria for a diagnosis of asthma were: (1) frequent wheezing attributable to certain allergens or irritants; (2) bilateral wheezing on auscultation during the asthma attack, prolonged expiration; (3) reversible airway obstruction responding to bronchodilators; (4) ruling out other diseases that can present with wheezing, chest tightness, and cough.

The control participants were healthy volunteers aged between 18 and 22 years old, with an even distribution between males and females. The criteria for the control group were: no symptom or history of other pulmonary diseases, no symptoms or history of allergy, and no first-degree relatives with a history of asthma or atopy. The age group of 18–22 years old allowed enough time to rule out the possibility that the control subjects could develop asthma or any signs of allergies. The control participants and the asthma patients were not related to each other.

Approval of this study was obtained from the Ethical Committee by the Ministry of Life and Quality of Life of the Republic of Mauritius.

Genotype detection

Genomic DNA was collected and isolated from an oral mucosa swab using a DNA extraction kit (Tiangen, Beijing, China). The 10 SNP loci were genotyped by TaqMan real-time quantitative polymerase chain reaction (RT-PCR; ABI 9700; Applied Biosystems, Foster City, CA). The reaction was performed in a 384-well plate format. Each well contained FAM-labeled and VIC-labeled probes. The total volume of 10 μ L included 10 ng of genomic DNA, 5 μ L of TaqMan Universal Master Mix (Applied Biosystems), 0.2 μ L of TaqMan SNP genotyping assay mix, and 2.5 μ L of RNase. Cycling conditions included one cycle at 95°C for 10 min, 40 cycles at 95°C for 15 sec, and 40 cycles at 60°C for 60 sec. Negative controls were included in each PCR reaction to avoid any contamination. After RT-PCR, each sample was automatically determined by measuring allele-specific final fluorescence in the ABI Prism 9700HT detection system, using the SDS 2.2 software for allele discrimination (Applied Biosystems). The assay ID for each SNP is listed in Table 1.

TABLE 1. ASSAY ID FOR EACH SNP

Primer	Assay ID
rs569108	C__900116_10
rs1441586	C__1842226_10
rs1042713	C__2084764_20
rs1801275	C__2351160_20
rs1805010	C__2769554_10
rs2243250	C__16176216_10
rs20541	C__2259921_20
rs1295686	C__8932053_10
rs1800925	C__8932056_10
rs4950928	C__27832042_10

SNP, single nucleotide polymorphism.

Statistical analysis

Statistical analyses were performed using IBM SPSS Statistics for Windows v19 (IBM Corp., Armonk, NY). The Hardy–Weinberg equilibrium was estimated using the chi-square test. Differences in genotype distribution between the experimental and control group were analyzed using the chi-square test. A p -value of <0.05 was considered statistically significant.

Results

No statistically significant differences ($p>0.05$) were found between the experimental and control group in genotype distribution among nine of the loci (MS4A2 E237G, MS4A2 C-109T, ADRB2 R16G, IL4RA Q551R, IL4RA I75V, IL4 C-590T, IL13 A2044G, IL13 C-1112T, and CHI3L1 C-131G). However, the frequency of IL13 C1923T TT in the asthma group was significantly higher than in the control group (odds ratio=2.119, $p=0.033$) suggesting that carriers of IL13 C1923T TT in the Mauritian population may have a more significant risk of developing asthma (Table 2).

Discussion

Asthma is considered to be the most common chronic childhood disease, and its pathogenesis is extremely complex and not fully understood, although the correlation of a variety of genetic loci and multiple environmental factors have been suggested as significant determinants of this disease.^{20,21} The current study was based on children aged between 3 and 12 years and who had been diagnosed with asthma for at least 1 year. They were also still following treatment for their recent episodes of wheezing.

Following the completion of the Human Genome Project, analysis of SNPs has become the newest approach in the detection and localization of the genetic determinants of human disease. During the past decades, numerous studies have been done to assess the role of specific genes and SNPs in the development of the asthmatic phenotype. Polymorphisms within IL-13 genes have been associated with the development of asthma in populations from Korea,²² the UK,²³ and Spain.²⁴ This study did not find a significant difference in IL13 C1923T TT between the experimental and control group. Wu *et al.* suggested that the T allele of the IL-13 C1923T was significantly associated with an increased risk of asthma in pediatric asthma patients in Middle

TABLE 2. DISTRIBUTION OF SNPs IN CHILDREN OF MAURITIAN POPULATION

SNP	rs Number	Group	n	Genotype			p-Value	OR (95% CI)
IL13 A2044	20541	Control	189	AA	AG	GG	0.78	1.199 (0.801–1.794)
				0.063	0.492	0.444		
				0.115	0.396	0.490		
ADRB2 R16G	1042713	Control	188	AA	AG	GG	0.811	1.056 (0.678–1.643)
				0.229	0.484	0.287		
				0.199	0.503	0.298		
FcER1 E237G	569108	Control	189	AA	AG	GG	0.991	0.984 (0.678–1.643)
				0.868	0.127	0.005		
				0.885	0.109	0.005		
IL13 C1923T	1295686	Control	186	CC	CT	TT	0.033	2.119 (0.678–1.643)
				0.414	0.516	0.07		
				0.429	0.434	0.137		
FcER1 C-109T	1441586	Control	188	CC	CT	TT	0.78	0.994 (0.591–1.67)
				0.351	0.463	0.186		
				0.291	0.524	0.185		
IL13 C-1112T	1800925	Control	187	CC	CT	TT	0.816	1.13 (0.401–3.182)
				0.594	0.369	0.037		
				0.632	0.326	0.042		
IL4RA Q551R	1801275	Control	189	AA	AG	GG	0.784	0.865 (0.307–2.436)
				0.593	0.365	0.042		
				0.521	0.442	0.037		
IL4RA I75V	1805010	Control	188	AA	AG	GG	0.151	1.056 (0.678–1.643)
				0.340	0.473	0.186		
				0.328	0.425	0.247		
IL4 C-590T	2243250	Control	189	CC	CT	TT	0.288	1.471 (0.72–3.006)
				0.667	0.259	0.074		
				0.542	0.353	0.105		
CHI3L1 C-131G 4950928	Control	189	0.64	0.333	0.026	1.187	0.78 (0.356–3.958)	
		Patients	192	0.635	0.333	0.031		

rs, reference SNP; OR, odds ratio; CI, confidence interval.

China.²⁵ However, no research has previously been done to investigate the genes and SNPs predisposing to asthma in the Mauritian population. The rs1295686 has been associated with the dysregulation of total IgE,²⁶ which is a major factor in the development of asthma,²⁷ but its role in the pathogenesis of asthma for the pediatric population has not been fully understood.

No statistically significant differences ($p > 0.05$) were found between the experimental and control group in genotype distribution among nine of the loci (MS4A2 E237G, MS4A2 C-109T, ADRB2 R16G, IL4RA Q551R, IL4RA I75V, IL4 C-590T, IL13 A2044G, IL13 C-1112T, and CHI3L1 C-131G). This contradicts previous reports showing an association between the pathogenesis of asthma and IL4 C-590T,¹⁵ IL13 C-1112T,²⁸ IL4RA I75V,²⁹ MS4A2 E237G,³⁰ ADRB2 R16G, and MS4A2 C-109T.³¹ This may be due to the diverse genetic backgrounds in populations of different nationalities or to the small size of the present sample. Further investigations could be considered with different nationalities.

Asthma is a multi-genetic disorder, and its pathogenesis is usually associated with the interaction of several SNP loci.^{32,33} Further studies on Mauritian children with a larger sample size and a wider SNP loci choice should be done to set up a possible molecular model for the prediction and diagnosis of asthma in the Mauritian population.

Acknowledgments

Grant sponsor: The National Natural Science Foundation of China, General Program (contract grant number: 30972750, 30872805); Science and Technology Commission of Shanghai Municipality, Key Technologies R&D Program (contract grant number: 10DZ1951000).

Author Disclosure Statement

No competing financial interests exist.

References

- Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. *Allergy* 2004;59:469–478.
- Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2009. *Vital Health Stat* 10 2009;239:1–80.
- Leung TF, Tang NL, Chan IH, et al. Distribution in allele frequencies of predisposition-to-atopy genotypes in Chinese children. *Pediatr Pulmonol* 2002;34:419–424.
- Leung TF, Chan IH, Wong GW, et al. Association between candidate genes and lung function growth in Chinese asthmatic children. *Clin Exp Allergy* 2007;37:1480–1486.
- Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. *J Allergy Clin Immunol* 2001;107:429–440.

6. Ober C, Hoffjan S. Asthma genetics 2006: the long and winding road to gene discovery. *Genes Immun* 2006;7:95–100.
7. Kim SH, Bae JS, Holloway JW, et al. A polymorphism of MS4A2 (-109T>C) encoding the beta-chain of the high-affinity immunoglobulin E receptor (FcepsilonR1beta) is associated with a susceptibility to aspirin intolerant asthma. *Clin Exp Allergy* 2006;36:877–883.
8. Kim YK, Park HW, Yang JS, et al. Association and functional relevance of E237G, a polymorphism of the high-affinity immunoglobulin E-receptor beta chain gene, to airway hyperresponsiveness. *Clin Exp Allergy* 2007;37:592–598.
9. Cui T, Wang L, Wu J, Xie J. The association analysis of FcepsilonR1beta with allergic asthma in a Chinese population. *Chin Med J (Engl)* 2003;116:1875–1878.
10. McKenzie AN, Li X, Largaespada DA, et al. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. *J Immunol* 1993;150:5436–5444.
11. Lachheb J, Chelbi H, Ammar J, et al. Promoter polymorphism of the IL-13 gene is associated with atopic asthma in Tunisian children. *Int J Immunogenet* 2008;35:63–68.
12. Yang H, Dong H, Dai Y, Zheng Y. Association of interleukin-13 C-1112T and G+2044A polymorphisms with asthma: a meta-analysis. *Respirology* 2011;16:1127–1135.
13. Granada M, Wilk JB, Tuzova M, et al. A genome-wide association study of plasma total IgE concentrations in the Framingham Heart Study. *J Allergy Clin Immunol* 2012;129:840–845.
14. Tiotiu A, Todea D, Tiotiu D, Sandor V. The distribution and polymorphism of beta-2-adrenoreceptors in the bronchi. *Pneumologia* 2005;54:177–180.
15. Li Y, Guo B, Zhang L, Han J, Wu B, Xiong H. Association between C-589T polymorphisms of interleukin-4 gene promoter and asthma: a meta-analysis. *Respir Med* 2008;102:984–992.
16. Risma KA, Wang N, Andrews RP, et al. V75R576 IL-4 receptor alpha is associated with allergic asthma and enhanced IL-4 receptor function. *J Immunol* 2002;169:1604–1610.
17. Ober C, Tan Z, Sun Y, et al. Effect of variation in *CHI3L1* on serum YKL-40 level, risk of asthma, and lung function. *N Engl J Med* 2008;358:1682–1691.
18. Nie W, Zang Y, Chen J, Xiu Q. Association between interleukin-4 receptor α chain (IL4RA) I50V and Q551R polymorphisms and asthma risk: an update meta-analysis. *PLoS One* 2013;8:e69120.
19. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. *Am Rev Respir Dis* 1987;136:225–244.
20. Maddox L, Schwartz DA. The pathophysiology of asthma. *Annu Rev Med* 2002;53:477–498.
21. Sengler C, Lau S, Wahn U, Nickel R. Interactions between genes and environmental factors in asthma and atopy: new developments. *Respir Res* 2002;3:7.
22. Park HW, Lee JE, Kim SH, et al. Genetic variation of IL13 as a risk factor of reduced lung function in children and adolescents: a cross-sectional population-based study in Korea. *Respir Med* 2009;103:284–288.
23. Black S, Teixeira AS, Loh AX, et al. Contribution of functional variation in the IL13 gene to allergy, hay fever and asthma in the NSHD longitudinal 1946 birth cohort. *Allergy* 2009;64:1172–1178.
24. Llanes E, Quiralte J, López E, et al. Analysis of polymorphisms in olive pollen allergy: IL13, IL4RA, IL5 and ADRB2 genes. *Int Arch Allergy Immunol* 2009;148:228–238.
25. Wu X, Li Y, Chen Q, et al. Association and gene-gene interactions of eight common single-nucleotide polymorphisms with pediatric asthma in middle china. *J Asthma* 2010;47:238–244.
26. Granada M, Wilk JB, Tuzova M, et al. A genome-wide association study of plasma total IgE concentrations in the Framingham Heart Study. *J Allergy Clin Immunol* 2012;129:840–845.e21.
27. Oettgen HC, Geha RS. IgE regulation and roles in asthma pathogenesis. *J Allergy Clin Immunol* 2001;107:429–440.
28. Kim HB, Lee YC, Lee SY, et al. Gene-gene interaction between IL-13 and IL-13Ralpha1 is associated with total IgE in Korean children with atopic asthma. *J Hum Genet* 2006;51:1055–1062.
29. Risma KA, Wang N, Andrews RP, et al. V75R576 IL-4 receptor alpha is associated with allergic asthma and enhanced IL-4 receptor function. *J Immunol* 2002;169:1604–1610.
30. Kim YK, Park HW, Yang JS, et al. Association and functional relevance of E237G, a polymorphism of the high-affinity immunoglobulin E-receptor beta chain gene, to airway hyperresponsiveness. *Clin Exp Allergy* 2007;37:592–598.
31. Li H, Xiaoyan D, Quanhua L, et al. Single-nucleotide polymorphisms in genes predisposing to asthma in children of Chinese Han nationality. *J Investig Allergol Clin Immunol* 2009;19:391–395.
32. Chan IH, Leung TF, Tang NL, et al. Gene-gene interactions for asthma and plasma total IgE concentration in Chinese children. *J Allergy Clin Immunol* 2006;117:127–133.
33. Kabesch M, Schedel M, Carr D, et al. IL-4/IL-13 pathway genetics strongly influence serum IgE levels and childhood asthma. *J Allergy Clin Immunol* 2006;117:269–274.

Address correspondence to:
 Yi Xiao Bao, PhD
 Department of Pediatrics
 Xin Hua Hospital
 1665 Kong Jiang Road
 Shanghai 200092
 China

E-mail: drsmilebao@163.com

Received for publication December 12, 2014; accepted after revision February 1, 2015.